Detalhe da pesquisa
1.
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies.
J Pharmacokinet Pharmacodyn
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700803
2.
Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
J Pharmacokinet Pharmacodyn
; 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38639818
3.
Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy.
Br J Clin Pharmacol
; 88(3): 1189-1201, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34449090
4.
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
J Pharmacokinet Pharmacodyn
; 49(3): 381-394, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35166967
5.
Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization.
Br J Clin Pharmacol
; 87(3): 1359-1368, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32808306
6.
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Pharm Res
; 37(12): 252, 2020 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33258982
7.
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Br J Clin Pharmacol
; 85(9): 1935-1945, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31050355
8.
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Br J Clin Pharmacol
; 85(7): 1495-1506, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30866056
9.
Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.
J Pharmacokinet Pharmacodyn
; 45(1): 23-34, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28918570
10.
Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
J Pharmacokinet Pharmacodyn
; 44(5): 463-475, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28725976
11.
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
J Pharmacokinet Pharmacodyn
; 44(6): 537-548, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28918591
12.
Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
J Pharmacokinet Pharmacodyn
; 43(3): 243-57, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993283
13.
Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.
Antimicrob Agents Chemother
; 59(11): 6774-81, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26282419
14.
A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
J Pharmacol Exp Ther
; 355(2): 288-96, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26359312
15.
Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.
J Pharmacokinet Pharmacodyn
; 42(3): 225-36, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25821064
16.
Target-mediated drug disposition model and its approximations for antibody-drug conjugates.
J Pharmacokinet Pharmacodyn
; 41(1): 35-47, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24322877
17.
Methods to detect non-compliance and reduce its impact on population PK parameter estimates.
J Pharmacokinet Pharmacodyn
; 41(3): 279-89, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24952228
18.
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
CPT Pharmacometrics Syst Pharmacol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622879
19.
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
Adv Drug Deliv Rev
; 207: 115193, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311111
20.
Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
CPT Pharmacometrics Syst Pharmacol
; 12(12): 2013-2026, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994400